Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Assembly Biosciences (ASMB) Net Income towards Common Stockholders: 2016-2025

Historic Net Income towards Common Stockholders for Assembly Biosciences (ASMB) over the last 9 years, with Sep 2025 value amounting to -$9.2 million.

  • Assembly Biosciences' Net Income towards Common Stockholders rose 4.34% to -$9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$37.2 million, marking a year-over-year increase of 4.03%. This contributed to the annual value of -$40.2 million for FY2024, which is 34.38% up from last year.
  • As of Q3 2025, Assembly Biosciences' Net Income towards Common Stockholders stood at -$9.2 million, which was down 4.29% from -$8.8 million recorded in Q2 2025.
  • Over the past 5 years, Assembly Biosciences' Net Income towards Common Stockholders peaked at -$8.8 million during Q1 2025, and registered a low of -$62.8 million during Q4 2021.
  • In the last 3 years, Assembly Biosciences' Net Income towards Common Stockholders had a median value of -$9.6 million in 2024 and averaged -$11.7 million.
  • As far as peak fluctuations go, Assembly Biosciences' Net Income towards Common Stockholders slumped by 461.45% in 2021, and later soared by 52.10% in 2024.
  • Over the past 4 years, Assembly Biosciences' Net Income towards Common Stockholders (Quarterly) stood at -$62.8 million in 2021, then reached -$11.0 million in 2023, then climbed by 5.72% to -$10.3 million in 2024, then grew by 4.34% to -$9.2 million in 2025.
  • Its Net Income towards Common Stockholders was -$9.2 million in Q3 2025, compared to -$8.8 million in Q2 2025 and -$8.8 million in Q1 2025.